In focus
Latest feed
D3 Bio Unveils Breakthrough First‑Line Results for ELISRASIB at ASCO 2026
D3 Bio’s First‑Line Data Shows Landmark Efficacy of Elisrasib in KRAS G12C‑Positive NSCLC
A Significant Setback: Arcus Biosciences Halts Key Lung Cancer Trial with Gilead
Summit Therapeutics on the Cusp: A Dual-Action Lung Cancer Drug Faces its Moment of Truth
